Craif, Inc. Craif and Tokuyama Central Hospital have started a prospective clinical study to verify the useful ness of miSignal(R)︎ for hereditary breast cancer and ovarian cancer syndrome (HBOC)

Craif Co., Ltd.
Craif Initiates Prospective Clinical Study with Tokuyama Central Hospital to Validate Usefulness of miSignal(R)︎ for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)

Craif Co., Ltd. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter Craif) is an independent administrative agency,
Organization for Promotion of Community Health Care Tokuyama Central Hospital (location: Shunan City, Prefecture, director: Fumitaka Numa, hereinafter Tokuyama Central Hospital). signed a joint research agreement with With the conclusion of this agreement, Craif and Tokuyama Central Hospital (responsible investigator: Yoshiaki Yamagata, Department of Obstetrics and Gynecology, Tokuyama Central Hospital) will start joint research on “miSignal cancer screening research for hereditary breast cancer and ovarian cancer syndrome”. [Imaged41883-79-4a5aa6fcfe0bac783a28-0.png&s3=41883-79-67c67671a01ecd6549581f9a69bf5a7f-1004x308.png
About this research
Ovarian cancer is a disease that affects about 10,000 people a year in Japan, and because there are few subjective symptoms in the early stages, about half of the cases are stage III and IV advanced cancer at the time of diagnosis, and the prognosis for these is poor. 10-15% of ovarian cancers are thought to be developed with a strong involvement of genetic factors. and Ovarian Cancer (HBOC). Although there are recommended routine screenings (surveillance) for BRCA1/2 pathogenic variant carriers (HBOC patients) who have not yet developed ovarian cancer, no surveillance method has been established to reduce mortality. The current situation is that we do not.
As a new cancer screening test, miSignal (R) developed by Craif Co., Ltd. is a test that uses urine as a sample to identify and analyze cancer-specific miRNA to screen for cancer risk. The development of ovarian cancer is progressing in particular, and it is reported that good detection performance can be expected even for patients with stage I and II ovarian cancer. This study prospectively validates the performance of miSignal(R) for early detection of ovarian cancer in BRCA1/2 pathogenic variant carriers by routinely administering miSignal(R) to HBOC patients. We will estimate the appropriate monitoring frequency and consider the possibility of reducing mortality from ovarian, fallopian tube, and peritoneal cancers. *: Take, S. et al., (2021) Urinary MicroRNAs as Biomarkers for Early Detection of Ovarian Cancer. European Society for Medical Oncology (ESMO) congress.
About Craif
Craif is a Nagoya University-launched venture company founded in May 2018. By comprehensively capturing microRNAs from urine using materials that Japan is proud of, combining them with AI (artificial intelligence) and applying them to medical care, we will be able to detect diseases at an early stage and provide personalized medicine, mainly in the area of ​​cancer. We are working on next-generation inspection development to realize Through collaboration with the world’s leading companies and organizations in the medical and healthcare fields, we will promote our vision of “realizing a society where people can live out their natural lives.” For more information, please visit
About miSignal(R)︎
 miSignal(R)️ (My Signal) is a cancer screening test that focuses on microRNAs (hereinafter referred to as miRNAs) that play an important role in the onset, progression, and metastasis of cancer. Proprietary technology efficiently captures minute amounts of miRNA in urine and detects early cancer risks with high accuracy. The biggest feature of this service is that it is painless. Just by providing urine to medical institutions, you can easily check the risk of cancer without any burden. For details, please see the website ( Details about this release:


%d bloggers like this: